Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder

Report of a case and review of the literature

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary cutaneous small/medium-sized T-cell lymphoma (PCSM-TCL), which was included in the World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as primary cutaneous small/medium-sized T-cell lymphoproliferative disorder (PCSM-TCLPD) because of its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, although there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors. PCSM-TCLPD retained its designation as a provisional entity under the updated WHO-EORTC guidelines; however, additional cases of PCSM-TCLPD are needed to shed more light on this rare disorder.

Original languageEnglish (US)
Pages (from-to)944-947
Number of pages4
JournalJournal of Cutaneous Pathology
Volume44
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Lymphoproliferative Disorders
T-Lymphocytes
Skin
Organizations
T-Cell Lymphoma
Skin Neoplasms
Research
Lymphoma
Guidelines
Neoplasms
Therapeutics

Keywords

  • dermatology
  • lymphoid neoplasms
  • lymphoma
  • lymphoproliferative disorder

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Dermatology

Cite this

@article{5cbe7e01c6ec49d5a1e10af0da51a5a1,
title = "Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature",
abstract = "Primary cutaneous small/medium-sized T-cell lymphoma (PCSM-TCL), which was included in the World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as primary cutaneous small/medium-sized T-cell lymphoproliferative disorder (PCSM-TCLPD) because of its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, although there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors. PCSM-TCLPD retained its designation as a provisional entity under the updated WHO-EORTC guidelines; however, additional cases of PCSM-TCLPD are needed to shed more light on this rare disorder.",
keywords = "dermatology, lymphoid neoplasms, lymphoma, lymphoproliferative disorder",
author = "Brett Keeling and Gavino, {Alde Carlo P.} and Joan Admirand and Anthony Soldano",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/cup.13011",
language = "English (US)",
volume = "44",
pages = "944--947",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder

T2 - Report of a case and review of the literature

AU - Keeling, Brett

AU - Gavino, Alde Carlo P.

AU - Admirand, Joan

AU - Soldano, Anthony

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Primary cutaneous small/medium-sized T-cell lymphoma (PCSM-TCL), which was included in the World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as primary cutaneous small/medium-sized T-cell lymphoproliferative disorder (PCSM-TCLPD) because of its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, although there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors. PCSM-TCLPD retained its designation as a provisional entity under the updated WHO-EORTC guidelines; however, additional cases of PCSM-TCLPD are needed to shed more light on this rare disorder.

AB - Primary cutaneous small/medium-sized T-cell lymphoma (PCSM-TCL), which was included in the World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as primary cutaneous small/medium-sized T-cell lymphoproliferative disorder (PCSM-TCLPD) because of its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, although there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors. PCSM-TCLPD retained its designation as a provisional entity under the updated WHO-EORTC guidelines; however, additional cases of PCSM-TCLPD are needed to shed more light on this rare disorder.

KW - dermatology

KW - lymphoid neoplasms

KW - lymphoma

KW - lymphoproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=85031713948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031713948&partnerID=8YFLogxK

U2 - 10.1111/cup.13011

DO - 10.1111/cup.13011

M3 - Article

VL - 44

SP - 944

EP - 947

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 11

ER -